Analyse coût-efficacité des stratégies de prise en charge des patients schizophrènes : place d’un antipsychotique atypique sous forme injectable à libération prolongée

Almond, 2000, Cost analysis of the treatment of schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol, Pharmacoeconomics, 17, 383, 10.2165/00019053-200017040-00008

Barnes, 1994, Long-term depot antipsychotics A risk-benefit assessment, Drug Saf, 10, 464, 10.2165/00002018-199410060-00005

Béresniak, 1995

Ministère du travail et des affaires sociales. Bulletin Officiel Solidarité Santé, n° 96/6bis, 1996.

Casadebaig, 2001, Caractéristique de la population prise en charge par les secteurs de psychiatrie générale en 1993 et 1998 Évolution clinique et démographique, Rev Epidemiol Sant Publ, 49, 513

Chue, 2002, Hospitalisation rates in patients during long-term treatment with long-acting risperidone injection, Int J Clin Neuropsychopharmacol, 5, S128

Chue, 2002, One year hospitalisation rates in patients with schizophrenia during long-term treatment with long-acting risperidone, Val Health, 5, 229, 10.1016/S1098-3015(10)61074-1

Csernansky, 2002, A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia, N Engl J Med, 346, 16, 10.1056/NEJMoa002028

Eerdekens, 2002, Long-term safety and efficacy of Risperdal Consta TM, the long-acting injection formulation of risperidone, Int J Clin Neuropsychopharmacol, 5, S126

Fédération française de psychiatrie. Conférence de Consensus – Stratégies thérapeutiques à long terme dans les psychoses schizophréniques. Paris, 13-14 janvier 1994

Foster, 1999, Olanzapine : a pharmacoeconomic review of its use in schizophrenia, Pharmacoeconomics, 15, 611, 10.2165/00019053-199915060-00008

Fratta, 2002, Olanzapine dans le traitement de la schizophrénie Évaluation clinique, Dos CNHIM, 1

Gaebel, 1987, Prospective study of course of illness in schizophrenia : part III Treatment and outcome, Schizophr Bull, 13, 307, 10.1093/schbul/13.2.307

Gerlach, 1995, Depot neuroleptics in relapse prevention : advantages and disadvantages, Int Clin Psychopharmacol, 9, 17, 10.1097/00004850-199501005-00004

Heyscue, 1998, Compliance with depot antipsychotic medication by patients attending outpatient clinics, Psychiatr Serv, 49, 1232, 10.1176/ps.49.9.1232

Rabinowitz, 2001, Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics, Am J Psychiatry, 158, 266, 10.1176/appi.ajp.158.2.266

Remington, 1995, Depot neuroleptic therapy : clinical considerations, Can J Psychiatry, 40, S5

Rouillon, 1994, Étude de la prise en charge thérapeutique des schizophrènes et son coût, Encephale, 20, 303

Rouillon, 1997, Some aspects of the costs of schizophrenia in France, Pharmacoeconomics, 11, 578, 10.2165/00019053-199711060-00006